Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Lung, Small Cell
Phase III
Adults
Mol. targeted/Immunotherapy/Biologics
Blinded Drug
Iams, Wade
International
Vanderbilt University
08-09-2019
Treatment
VICCTHO1901
NCT03703297

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Histologically or cytologically documented limited-stage small cell lung cancer (stage I-III).

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: